Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

(2020) Kai Duan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunogenicity of a DNA vaccine candidate for COVID-19

(2020) Trevor R. F. Smith et al.   Nature Communications

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

(2020) Lihong Liu et al.   NATURE

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

(2020) Daming Zhou et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

(2020) Xiangyang Chi et al.   SCIENCE

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size

(2020) Hong Zhao et al.   BIOMEDICINE & PHARMACOTHERAPY

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

(2020) Jiandong Huo et al.   Cell Host & Microbe

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

(2020) Jianhui Nie et al.   Nature Protocols

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

(2020) Monir Ejemel et al.   Nature Communications

Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies

(2020) Kimberley Steeds et al.   Scientific Reports

Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations

(2020) Julia A. Tree et al.   BRITISH JOURNAL OF PHARMACOLOGY

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies

(2012) Marisol Simões et al.   BIOLOGICALS

Development of a focus reduction neutralization test (FRNT) for detection of mumps virus neutralizing antibodies

(2009) Sunil R. Vaidya et al.   JOURNAL OF VIROLOGICAL METHODS

Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination

(2008) B.J. Cohen et al.   VACCINE